Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Lactobacillus reuteri 100000000 UNT Chewable Tablet

Known as: Lactobacillus reuteri 100 Million Cells Chewable Tablet, Lactobacillus reuteri 100 Million UNT Chewable Tablet, Lactobacillus reuteri 100,000,000 UNT Chewable Tablet 
 
National Institutes of Health

Related topics

Related topics

3 relations
Chewable Tablet

Narrower (2)

Lactobacillus reuteri 100000000 UNT Chewable Tablet [BioGaia]Lactobacillus reuteri 100000000 UNT Chewable Tablet [Pedia-Lax Probiotic]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial…
BackgroundObesity is characterized by increased fat mass and is associated with the development of insulin resistance syndrome… Expand
  • figure 1
  • table 1
Highly Cited
2012
Highly Cited
2012
Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial
Background/Objectives:The percentage of hypercholesterolemic individuals not reaching their LDL-cholesterol (LDL-C) goal remains… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Highly Cited
2012
Highly Cited
2012
Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis
Background  Intestinal microbiota manipulation, one of the pathogenetic components of inflammatory bowel disease (IBD), has… Expand
Highly Cited
2012
Highly Cited
2012
Lactobacillus reuteri Prevents Diet-Induced Obesity, but not Atherosclerosis, in a Strain Dependent Fashion in Apoe−/− Mice
Objective To investigate whether the specific strains of Lactobacillus reuteri modulates the metabolic syndrome in Apoe−/− mice… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 4
Highly Cited
2011
Highly Cited
2011
Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults
Several studies have reported limited or no reduction in serum cholesterol in response to probiotic formulations. Recently… Expand
Highly Cited
2009
Highly Cited
2009
Oral colonization by Lactobacillus reuteri ATCC 55730 after exposure to probiotics.
OBJECTIVE The aim of this study was to investigate whether Lactobacillus reuteri ATCC 55730 can be detected in the oral cavity… Expand
Highly Cited
2007
Highly Cited
2007
Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial.
BACKGROUND An altered microbial exposure may underlie the increase of allergic diseases in affluent societies. Probiotics may… Expand
Highly Cited
2006
Highly Cited
2006
Salivary mutans streptococci and lactobacilli levels after ingestion of the probiotic bacterium Lactobacillus reuteri ATCC 55730 by straws or tablets
Objective. Previous studies have suggested that lactobacilli-derived probiotics in dairy products may affect oral ecology, but… Expand
2005
2005
Transformation ofLactobacillus reuteri with electroporation: Studies on the erythromycin resistance plasmid pLUL631
A high-frequency transformation system was developed forLactobacillus reuteri with the electroporation technique. With this… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Highly Cited
2005
Highly Cited
2005
Increasing work-place healthiness with the probiotic Lactobacillus reuteri: A randomised, double-blind placebo-controlled study
BackgroundShort term illnesses, usually caused by respiratory or gastrointestinal diseases are disruptive to productivity and… Expand
  • table 1
  • table 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE